甲状腺结节评估的当前视角:整合细胞形态学、超声风险分层与分子检测
本文综述甲状腺细针穿刺活检(FNAB)在当代甲状腺结节评估中的演变,强调其已从形态学筛查转向整合超声风险分层、细胞形态学判读、分子检测与风险适应管理的精准诊断路径,并讨论Bethesda第三版、WHO第五版分类及人工智能等新兴方向。
要点
- 甲状腺FNAB仍是术前评估基石,但已融入超声风险分层与分子检测的多维路径。
- Bethesda第三版与WHO第五版分类更新影响细胞判读与肿瘤分类。
- 分子分类器在不确定结节管理中作用扩展,人工智能等新方法亦在讨论中。
核心结论
- 甲状腺FNAB已从以形态学为主的筛查手段转变为精准诊断路径的核心组成部分。
研究设计与样本
- 本文为综述,总结甲状腺FNAB的适应证、标本充分性、Bethesda框架下细胞形态判读、不确定结节管理及分子分类器作用。
主要发现
- 过去十年甲状腺FNAB角色显著演变,反映超声风险分层系统进步与细胞学报告 refinements。
- Bethesda第三版、即将发布的WHO头颈细胞病理报告系统、分子检测整合及WHO第五版内分泌肿瘤分类修订共同推动这一转变。
- 当代实践将影像风险评、细胞形态判读、分子检测与风险适应管理策略相结合。
临床怎么用
- 外科病理学家与细胞病理学家需在 multidisciplinary 甲状腺结节管理中理解整合路径的实践意义。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Fine-needle aspiration biopsy (FNAB) remains the cornerstone of preoperative evaluation of thyroid nodules and represents one of the most enduring and successful applications of cytopathology in clinical medicine. Over the past decade, however, the role of thyroid FNAB has evolved considerably. This transformation reflects advances in ultrasound-based risk stratification systems and refinements in cytologic reporting, culminating in the third edition of the Bethesda System for Reporting Thyroid Cytopathology and ongoing international harmonization initiatives, including the forthcoming World Health Organization Reporting System for Head and Neck Cytopathology, the integration of molecular diagnostic testing into routine workflows, and major revisions in thyroid tumor classification introduced in the fifth edition of the WHO Classification of Endocrine and Neuroendocrine Tumours. Collectively, these developments have shifted thyroid FNAB from a predominantly morphologic screening modality to a central component of a multidimensional, precision-based diagnostic pathway. In contemporary practice, thyroid FNAB operates within an integrated clinical framework that combines imaging-based risk assessment, cytomorphologic interpretation, molecular testing, and risk-adapted management strategies. This review summarizes the current status of thyroid FNAB with emphasis on FNAB indications, specimen adequacy, cytomorphologic interpretation within the Bethesda framework, management of indeterminate thyroid nodules, and the expanding role of molecular classifiers. Emerging diagnostic and management approaches, including artificial intelligence, radiogenomics, active surveillance, and ablation therapies, are also discussed. Attention is given to the practical implications of these advances for surgical pathologists and cytopathologists who are engaged in multidisciplinary thyroid nodule management.
引用
- Pusztaszeri MP, Baloch ZW. Current Perspectives on Thyroid Nodule Evaluation: Integrating Cytomorphology, Ultrasound Risk Stratification, and Molecular Testing. Mod Pathol. 2026. PMID: 42468828. doi:10.1016/j.modpat.2026.101039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。